TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 4129.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
United Orthopedic Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
United Orthopedic Corporation’s forward annual dividend is NT$4.50 per share, paid annual. The forward yield is 5.87% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
United Orthopedic Corporation’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of NT$2.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow United Orthopedic Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spectrum of orthopedic needs. Its comprehensive range of hip and knee solutions includes various artificial hip joints, partial hip replacements, specialized joints for large trochanteric fractures, and Moore hip prostheses. Uniquely, it also designs and supplies custom artificial hip and knee joints specifically tailored for individual tumor patients, alongside standard artificial knee replacement joints, revision systems, and restricted artificial knee joints. For spinal care, United Orthopedic manufactures vertebral fixation devices. Furthermore, its portfolio extends to injury and trauma products, which encompass a variety of orthopedic internal fixation items, bone plates, bone nails, bone pins, and bone screws. The company also functions as an OEM supplier for orthopedic internal fixation solutions and provides specialized lamb salvage systems. Beyond implants, United Orthopedic Corporation delivers orthopedic surgical equipment and the machinery necessary for its manufacturing. It also trades in special metal and plastic materials, actively engaging in the import and export of its products across international markets. With a global footprint, the company conducts business in Taiwan, across Asia, the Americas, Europe, Africa, and Australia. Established in 1993, United Orthopedic Corporation is headquartered in New Taipei City, Taiwan, and operates as a subsidiary of Chi-Yi Investment Co. Ltd.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:49 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | NT$1.98+50.0% vs estimate | NT$1.30B+0.01% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | NT$1.70+8.28% vs estimate | NT$1.35B-0.38% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | NT$1.43+0.7% vs estimate | NT$1.13B-16.7% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$73.00-NT$1.10 (-1.48%)
A Plus Biotechnology Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 20.65% below the high.
NT$24.00NT$0.00 (0.0%)
Wiltrom Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 20.66% below the high.
NT$29.90-NT$0.60 (-1.97%)
A-SPINE Asia Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.17% below the high.
